Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the efficacy of pasireotide LAR in pancreatic and duodenum NETs (Insulinoma, Gastrinoma, VIPoma, and Glucagonoma) based on disease specific primary biochemical tumor markers.
Critère d'inclusion
- The following tumors are included:
- 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,
- 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)
- 3. Ectopic ACTH-secreting (EAS) tumors
- 4. Nelson's syndrome